Please login to the form below

Not currently logged in

Almirall launches call on AlmirallShare to find innovative therapies for skin diseases

Since its launch, the R&D platform has received over 560 proposals from over 50 countries


Almirall has made a seventh call via its AlmirallShare platform for new proposals to initiate collaborations in dermatological research.

This year’s call to action is focused on exploring potential partnerships to optimise the value of preclinical and clinical stage assets for people who have a dermatological condition.

The company is keen to address scientists affiliated with start-ups, biotech companies, pharmaceutical companies, universities and research centres globally, and those interested in taking part can submit their proposals at until 31 October 2022.

Almirall’s open innovation R&D platform has gained the attention of over 1,100 scientists and has subsequently received 560 proposals from over 50 countries since its launch.

Scientific experts at Almirall will assess the submitted proposals and select those that are the best fit for the call requirements and demonstrate the potential to begin a long-term business partnership with the company.

Proposals put forward on the platform should focus on preclinical and clinical assets from any therapeutic modality, including small molecules, biologics or advanced therapies.

The assets may have the potential to target immuno-inflammatory pathways for dermatological indications like atopic dermatitis, hidradenitis suppurativa, alopecia areata or vitiligo.

The assets may also be suitable for non-melanoma skin cancer such as basal and squamous cell carcinoma and cutaneous T cell lymphoma, or rare dermatological indications such as epidermolysis bullosa, pemphigus vulgaris, bullous pemphigoid, among others.

The company added that for preclinical assets ‘compelling evidence of in vitro and in vivo efficacy will be highly valuable’.

Maribel Crespo, AlmirallShare leader, said: “Since its launch five years ago, AlmirallShare has consolidated its position as a powerful channel for scientific exchange and cross-functional collaboration. It has enabled us to forge unique and valuable alliances with scientists that have led to long-term relationships.

“With this new call for proposals, we want to continue fostering scientific creativity by bringing people and cultures from around the world to accelerate progress and drive the development of novel dermatological medical solutions.”

Article by
Fleur Jeffries

20th July 2022

From: Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company

The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....